Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen, bone mineral density
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.
3d
on MSN
Amgen stock falls as analysts mull over weight loss drug’s bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone ...
NBC Los Angeles
4d
Amgen says no concerns around weight loss drug's bone density data after stock falls
Amgen
said there is no link between its experimental weight loss drug, MariTide, and changes in
bone
density
. The ...
2d
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
2d
What’s Happening With Amgen Stock?
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
MarketWatch
3d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen
on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of
bone
mineral
density
.
Amgen
shares fell more than 7% on Tuesday ...
3d
Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...
3d
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
STAT
3d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Hosted on MSN
3d
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -
Amgen
said on Wednesday there was no link between its experimental weight-loss drug and changes in
bone
...
Yahoo
2d
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Amgen
stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive
bone
...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback